Examples of using Decrease in haemoglobin in English and their translations into Croatian
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Anaemia(decrease in haemoglobin)a, b, Lymphopaenia.
Anemija(smanjena razina hemoglobina)a, b, limfopenija.That treatment with STAYVEER is associated with a decrease in haemoglobin.
Liječenje STAYVEEROM povezano je s padom hemoglobina.Decrease in haemoglobin in your blood low red blood cell count.
Manjenje hemoglobina u vašoj krvi nizak broj crvenih krvnih stanica.TIMI Minor: Clinically apparent with 30-50 g/L decrease in haemoglobin.
TIMI manja: Klinički vidljiva, sa smanjenjem hemoglobina od 30-50 g/l.G/dL decrease in haemoglobin during any 4 week treatment period.
Sniženje hemoglobina za ≥ 2 g/dl tijekom bilo kojeg 4-tjednog razdoblja liječenja.TIMI Minor Bleed: Clinically apparent with 30 50 g/l decrease in haemoglobin.
Manje TIMI krvarenje: Klinički vidljiva, sa smanjenjem hemoglobina od 30-50 g/l.That STAYVEER causes a decrease in haemoglobin and the need for regular blood tests.
STAYVEER uzrokuje pad hemoglobina i potrebno je vršiti redovite krvne pretrage.The need for regular blood tests because Opsumit causes a decrease in haemoglobin;
Potreba za redovitim krvnim pretragama, jer Opsumit uzrokuje pad hemoglobina.Anaemia(decrease in haemoglobin)a, b, Neutropaenia decrease in absolute.
Anemija(smanjena razina hemoglobina)a, b, neutropenija TIMI Minor: Clinically apparent with 30-50 g/L decrease in haemoglobin.
Manje prema TIMI kriterijima: klinički značajno krvarenje uz smanjenje hemoglobina od 30-50 g/l.G/dL decrease in haemoglobin during any 4 week period during treatment permanent dose reduction.
Pad hemoglobina za ≥ 2 g/dl tijekom bilo koja 4 tjedna trajanja liječenja trajno sniženje doze.That treatment with Volibris often causes a decrease in haemoglobin and haematocrit.
Liječenje lijekom Volibris često utječe na smanjenje hemoglobina i Decrease in haemoglobin(oxygen-carrying pigment in blood) and leukocytes white blood cells.
Snjiženje hemoglobina(krvnog pigmenta zaduženog za prijenos kisika) i leukocita bijelih krvnih stanica.None of these changes were associated with bleeding episodes or a decrease in haemoglobin.
Nijedna od ovih promjena nije bila povezana s epizodama krvarenja ili sniženjem hemoglobina.This is characterised by a sustained decrease in haemoglobin despite an increase in Retacrit dosage.
To se očituje stalnim smanjenjem hemoglobina usprkos povećanju doze Retacrit.A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti- erythropoietin antibody testing.
Paradoksalno sniženje hemoglobina i razvoj jake anemije povezane s niskim brojem retikulocita znak je za prestanak terapije epoetinom i testiranje prisutnosti protutijela na eritropoetin.TIMI Major: Clinically apparent with>50 g/L decrease in haemoglobin or intracranial haemorrhage.
Značajno prema TIMI kriterijima:klinički značajno krvarenje uz smanjenje hemoglobina za> 50 g/l ili intrakranijalno krvarenje.A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti- erythropoietin antibody testing.
Paradoksalno sniženje vrijednosti hemoglobina i razvoj teške anemije povezan s niskim brojem retikulocita zahtijeva trenutni prekid terapije epoetinom i testiranje na antieritropoetinska antitijela.TIMI major bleeding was defined as intracranial bleeding or a decrease in haemoglobin concentration≥5 g/dl.
Veliko krvarenje TIMI definirano je kao intrakranijalno krvarenje ili smanjenje koncentracije hemoglobina od ≥5 g/dl.If tests show a clinically significant decrease in haemoglobin or haematocrit, and other causes have been excluded, consider reducing the dose of Volibris, or stopping treatment.
Ukoliko se zapazi klinički značajno smanjenje koncentracija hemoglobina ili hematokrita, a drugi su uzroci isključeni, treba razmotriti Major bleeding was defined in the PURSUIT trial as either an intracranial haemorrhage or a decrease in haemoglobin concentrations of more than 5 g/dl.
Velika krvarenja definirana su u PURSUIT ispitivanju ili kao intrakranijalno krvarenje ili kao pad koncentracija hemoglobina za više od 5 g/dl.PRCA in patients with Hepatitis C: A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti-erythropoietin antibody testing.
PRCA u bolesnika s hepatitisom C: Paradoksalno sniženje hemoglobina i razvoj teške anemije povezane s niskim brojem retikulocita zahtijeva prekid liječenja epoetinom i testiranje na antieritropoetinska antitijela.Macitentan may lead to more reduction of blood pressure and decrease in haemoglobin in patients with kidney problems.
Macitentan može dovesti do sniženja krvnog tlaka i smanjenja hemoglobina u bolesnika s oštećenjem bubrega.In the adult placebo-controlled studies, a decrease in haemoglobin concentration to below 10 g/dL from baseline was reported in 8.0% of bosentan-treated patients and 3.9% of placebo-treated patients see section 4.4.
U placebom kontroliranim studijama na odraslima, smanjenje koncentracije hemoglobina ispod 10 g/dl od početne vrijednosti prijavljeno je kod 8,0% bolesnika koji su dobivali bosentan i 3,9% bolesnika koji su dobivali placebo vidjeti dio 4.4.TIMI Major Bleed: Clinically apparent with>50 g/L decrease in haemoglobin or intracranial haemorrhage.
Veliko TIMI(Thrombolysis in Myocardial Infarction) krvarenje:Klinički vidljiva, sa smanjenjem hemoglobina> 50 g/l ili intrakranijalnim krvarenjem.PLATO Major Fatal/life-threatening: Fatal bleeding, OR any intracranial bleeding, OR intrapericardial with cardiac tamponade, OR with hypovolaemic shock or severe hypotension requiring pressors/inotropes or surgery OR clinically apparent with>50 g/L decrease in haemoglobin or≥4 red cell units transfused.
PLATO Velika Fatalna/opasna po život: Fatalna krvarenja, ILI bilo koje intrakranijalno krvarenje, ILI intraperikardijalno krvarenje sa srčanom tamponadom, ILI sa hipovlemijskim šokom ili teškom hipotenzijom koja zahtijeva lijekove za povišenje krvnog tlaka ili operaciju, ILIklinički vidljivo sa smanjenjem hemoglobina od> 50 g/l ili transfuzijom ≥4 jedinice eritrocita.This is characterised by a sustained decrease in haemoglobin despite an increase in epoetin alfa dosage see section 4.8.
To je karakterizirano nepekidnim sniženjem hemoglobina, usprkos povećanju doze epoetina alfa vidjeti dio 4.8.In a double-blind study in patients with PAH, macitentan 10 mg was associated with a mean decrease in haemoglobin versus placebo of 1 g/dL.
U dvostruko slijepom ispitivanju na bolesnicima s PAH-om, macitentan 10 mg povezan je s prosječnim padom koncentracije hemoglobina naspram placeba od 1 g/dl.Dry mouth low white blood cell and/or platelet count, decrease in haemoglobin in your blood, increase in triglycerides, lipase and/or bilirubin in your blood.
Uha usta nizak broj bijelih krvnih stanica i/ili trombocita, sniženje hemoglobina u krvi, povišenje triglicerida, lipaze i/ili bilirubina u krvi.Not known Decrease in haemoglobin, decrease in haematocrit, neutropenia, thrombocytopenia, increase of serum potassium, elevation of liver function values including increase of serum bilirubin, renal failure and impairment, elevation of serum creatinine, angioedema, myalgia, vasculitis, hypersensitivity including serum sickness.
Nepoznato Sniženje hemoglobina, 
